Celltrion Pharm, Inc. (068760.KQ)
KRW 61300.0
(-3.01%)
KRW 61300.0
(-3.01%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 539.00 KRW | -18.09% |
| 2022 | 626.83 KRW | -24.92% |
| 2021 | 834.84 KRW | 65.17% |
| 2020 | 505.43 KRW | 131.76% |
| 2019 | 218.08 KRW | 196.1% |
| 2018 | -226.92 KRW | -444.81% |
| 2017 | 65.81 KRW | 110.27% |
| 2016 | -640.85 KRW | -351.81% |
| 2015 | 254.50 KRW | -13.45% |
| 2014 | 294.05 KRW | 173.97% |
| 2013 | 107.33 KRW | -48.57% |
| 2012 | 208.70 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | 45.65 KRW | 166.65% |
| 2024 Q2 | 135.10 KRW | 195.73% |
| 2023 Q3 | 79.75 KRW | -68.74% |
| 2023 Q4 | 17.12 KRW | -78.53% |
| 2023 FY | - KRW | -18.09% |
| 2023 Q1 | 161.48 KRW | 8.04% |
| 2023 Q2 | 255.08 KRW | 57.96% |
| 2022 FY | - KRW | -24.92% |
| 2022 Q4 | 149.47 KRW | -22.16% |
| 2022 Q1 | 103.12 KRW | -16.24% |
| 2022 Q3 | 192.02 KRW | 5.37% |
| 2022 Q2 | 182.24 KRW | 76.73% |
| 2021 Q3 | 215.59 KRW | -32.56% |
| 2021 Q4 | 123.11 KRW | -42.9% |
| 2021 Q2 | 319.67 KRW | 81.11% |
| 2021 Q1 | 176.51 KRW | -31.89% |
| 2021 FY | - KRW | 65.17% |
| 2020 Q3 | 96.70 KRW | 3.67% |
| 2020 FY | - KRW | 131.76% |
| 2020 Q4 | 259.15 KRW | 167.99% |
| 2020 Q2 | 93.28 KRW | 73.64% |
| 2020 Q1 | 53.72 KRW | -47.59% |
| 2019 FY | - KRW | 196.1% |
| 2019 Q3 | 49.21 KRW | 2.14% |
| 2019 Q1 | 6.87 KRW | 108.16% |
| 2019 Q4 | 102.50 KRW | 108.29% |
| 2019 Q2 | 48.18 KRW | 601.31% |
| 2018 Q2 | -61.66 KRW | -676.26% |
| 2018 FY | - KRW | -444.81% |
| 2018 Q1 | 10.70 KRW | -96.5% |
| 2018 Q4 | -84.22 KRW | 8.55% |
| 2018 Q3 | -92.09 KRW | -49.35% |
| 2017 Q1 | -37.55 KRW | 94.92% |
| 2017 Q2 | 81.67 KRW | 317.5% |
| 2017 FY | - KRW | 110.27% |
| 2017 Q4 | 305.73 KRW | 588.58% |
| 2017 Q3 | 44.40 KRW | -45.63% |
| 2016 Q3 | 34.66 KRW | 966.46% |
| 2016 FY | - KRW | -351.81% |
| 2016 Q1 | 48.31 KRW | 106.2% |
| 2016 Q2 | 3.25 KRW | -93.27% |
| 2016 Q4 | -739.80 KRW | -2234.45% |
| 2015 Q3 | 31.48 KRW | 271.23% |
| 2015 Q2 | 8.48 KRW | -81.48% |
| 2015 Q1 | 45.79 KRW | -53.38% |
| 2015 FY | - KRW | -13.45% |
| 2015 Q4 | -778.66 KRW | -2573.51% |
| 2014 Q3 | 48.45 KRW | -57.53% |
| 2014 FY | - KRW | 173.97% |
| 2014 Q4 | 98.23 KRW | 102.75% |
| 2014 Q2 | 114.07 KRW | 641.2% |
| 2014 Q1 | 15.39 KRW | 192.38% |
| 2013 Q3 | 81.64 KRW | 1637.02% |
| 2013 FY | - KRW | -48.57% |
| 2013 Q1 | 41.83 KRW | -11.45% |
| 2013 Q4 | -16.66 KRW | -120.41% |
| 2013 Q2 | 4.70 KRW | -88.76% |
| 2012 Q4 | 47.24 KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | -666.05 KRW | 180.925% |
| CMG Pharmaceutical Co., Ltd. | 46.00 KRW | -1071.739% |
| Huons Global Co., Ltd. | 3133.85 KRW | 82.801% |
| DongKook Pharmaceutical Co., Ltd. | 1073.13 KRW | 49.773% |
| Enzychem Lifesciences Corporation | -109.81 KRW | 590.848% |
| Humedix Co., Ltd. | 2512.11 KRW | 78.544% |
| Boditech Med Inc. | 1181.00 KRW | 54.361% |
| EuBiologics Co., Ltd. | -381.00 KRW | 241.47% |
| FutureChem Co.,Ltd | -303.61 KRW | 277.53% |
| Huons Co., Ltd. | 4261.00 KRW | 87.35% |
| BNC Korea Co., Ltd. | 388.00 KRW | -38.918% |
| AptaBio Therapeutics Inc. | -540.91 KRW | 199.647% |